Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies

BF Haynes, K Wiehe, P Borrow, KO Saunders… - Nature Reviews …, 2023‏ - nature.com
After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …

The unique biology of germinal center B cells

C Young, R Brink - Immunity, 2021‏ - cell.com
Germinal center (GC) B cells are the source of the high-affinity, class-switched antibodies
required for protective immunity. The unique biology of GC B cells involves iterative rounds …

Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health

CN Fries, EJ Curvino, JL Chen, SR Permar… - Nature …, 2021‏ - nature.com
Despite the overwhelming success of vaccines in preventing infectious diseases, there
remain numerous globally devastating diseases without fully protective vaccines, particularly …

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

M Caskey, T Schoofs, H Gruell, A Settler… - Nature medicine, 2017‏ - nature.com
Monoclonal antibody 10-1074 targets the V3 glycan supersite on the HIV-1 envelope (Env)
protein. It is among the most potent anti-HIV-1 neutralizing antibodies isolated so far. Here …

Broadly neutralizing antibodies to HIV and their role in vaccine design

DR Burton, L Hangartner - Annual review of immunology, 2016‏ - annualreviews.org
HIV employs multiple means to evade the humoral immune response, particularly the
elicitation of and recognition by broadly neutralizing antibodies (bnAbs). Such antibodies …

HIV-1 vaccines based on antibody identification, B cell ontogeny, and epitope structure

PD Kwong, JR Mascola - Immunity, 2018‏ - cell.com
HIV-1 vaccine development has been stymied by an inability to induce broadly reactive
neutralizing antibodies to the envelope (Env) trimer, the sole viral antigen on the virion …

Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site

TG Caniels, M Medina-Ramìrez, S Zhang… - Science …, 2024‏ - science.org
Eliciting potent and broadly neutralizing antibodies (bnAbs) is a major goal in HIV-1 vaccine
development. Here, we describe how germline-targeting immunogen BG505 SOSIP …

Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1

K Xu, P Acharya, R Kong, C Cheng, GY Chuang… - Nature medicine, 2018‏ - nature.com
A central goal of HIV-1 vaccine research is the elicitation of antibodies capable of
neutralizing diverse primary isolates of HIV-1. Here we show that focusing the immune …

Structure and immune recognition of trimeric pre-fusion HIV-1 Env

M Pancera, T Zhou, A Druz, IS Georgiev, C Soto… - Nature, 2014‏ - nature.com
The human immunodeficiency virus type 1 (HIV-1) envelope (Env) spike, comprising three
gp120 and three gp41 subunits, is a conformational machine that facilitates HIV-1 entry by …

mRNA vaccines: The future of prevention of viral infections?

P Rzymski, A Szuster‐Ciesielska… - Journal of medical …, 2023‏ - Wiley Online Library
Messenger RNA (mRNA) vaccines against COVID‐19 are the first authorized biological
preparations developed using this platform. During the pandemic, their administration has …